J Korean Med Sci.  2021 Oct;36(38):e272. 10.3346/jkms.2021.36.e272.

Contact-adjusted Immunity Levels against SARS-CoV-2 in Korea and Prospects for Achieving Herd Immunity

• Chun JY
• Jeong H
• Kim Y

• KMID: 2520780
• DOI: http://doi.org/10.3346/jkms.2021.36.e272

Abstract

The proportion of population vaccinated cannot be directly translated into the herd immunity. We have to account for the age-stratified contact patterns to calculate the population immunity level, since not every individual gathers evenly. Here, we calculated the contact-adjusted population immunity against severe acute respiratory syndrome coronavirus 2 in South Korea using age-specific incidence and vaccine uptake rate. We further explored options to achieve the theoretical herd immunity with age-varying immunity scenarios. As of June 21, 2021, when a quarter of the population received at least one dose of a coronavirus disease 2019 (COVID-19) vaccine, the contact-adjusted immunity level was 12.5% under the social distancing level 1. When 80% of individuals aged 10 years and over gained immunity, we could achieve a 58.2% contact-adjusted immunity level. The pros and cons of vaccinating children should be weighed since the risks of COVID-19 for the young are less than the elderly, and the long-term safety of vaccines is still obscure.

Keyword

SARS-CoV-2; COVID-19; Herd Immunity; Republic of Korea

Figure

• 

  Fig. 1 Age-specific contact patterns in South Korea under the different social distancing measures.13

• 

  Fig. 2 Contact-adjusted immunity level against COVID-19 (A) based on the reported age-specific incidence and vaccine uptake rates under the various social distancing measures, and (B) scenario modelling through raising immunity of each age group. Plain immunity was calculated by overall proportion of the population immune.COVID-19 = coronavirus disease 2019.*In sensitivity analysis, the lowest value is drawn if there are 1.2 times contacts for age groups under 20 (< 20 years) and 0.8 times contacts for age groups 20 years and over (≥ 20 years); and the highest is drawn if there are 0.8 times contacts for < 20 years groups and 1.2 times contacts for ≥ 20 years groups.

Reference

1. World Health Organization. WHO coronavirus (COVID-19) dashboard. Updated 2021. Accessed June 26, 2021. https://covid19.who.int/.

2. World Health Organization. COVID-19 virtual press conference transcript - 12 October 2020. Updated 2020. Accessed July 3, 2021. https://www.who.int/publications/m/item/covid-19-virtual-press-conference-transcript---12-October-2020.

3. Ryu S, Ali ST, Jang C, Kim B, Cowling BJ. Effect of nonpharmaceutical interventions on transmission of severe acute respiratory syndrome coronavirus 2, South Korea, 2020. Emerg Infect Dis. 2020; 26(10):2406–2410. PMID: 32487283.

4. Ministry of Health and Welfare (KR). Coronavirus disease-19, Republic of Korea. Updated 2021. Accessed June 26, 2021. http://ncov.mohw.go.kr/.

5. Brazeau N, Verity R, Jenks S, Fu H, Whittaker C, Winskill P, et al. Report 34: COVID-19 infection fatality ratio: estimates from seroprevalence. Updated 2020. Accessed June 28, 2021. https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-10-29-COVID19-Report-34.pdf.

6. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020; 382(13):1199–1207. PMID: 31995857.

7. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020; 20(9):e238–e244. PMID: 32628905.

8. Park SW, Bolker BM, Champredon D, Earn DJ, Li M, Weitz JS, et al. Reconciling early-outbreak estimates of the basic reproductive number and its uncertainty: framework and applications to the novel coronavirus (SARS-CoV-2) outbreak. J R Soc Interface. 2020; 17(168):20200144. PMID: 32693748.

9. Funk S, Knapp JK, Lebo E, Reef SE, Dabbagh AJ, Kretsinger K, et al. Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination. BMC Med. 2019; 17(1):180. PMID: 31551070.

10. Korea Disease Control and Prevention Agency. Press release: Korea COVID-19 update. Updated 2021. Accessed June 26, 2021. http://www.kdca.go.kr/board/board.es?mid=a20501000000&bid=0015&list_no=713774&act=view.

11. Crotty S. Hybrid immunity. Science. 2021; 372(6549):1392–1393.

12. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021; 384(23):2187–2201. PMID: 33882225.

13. Prem K, Zandvoort KV, Klepac P, Eggo RM, Davies NG, Cook AR, et al. Projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the COVID-19 era. PLOS Comput Biol. 2021; 17(7):e1009098. PMID: 34310590.

14. Ministry of Education (KR). Remote learning and school opening information. Updated 2021. Accessed June 26, 2021. https://www.moe.go.kr/sub/info.do?m=580201&page=580201&num=02&s=moe.

15. Google. COVID-19 community mobility reports. Updated 2021. Accessed June 26, 2021. https://www.google.com/covid19/mobility/.

16. Korean Statistical Information Service. Population projection for Korea. Updated 2021. Accessed June 26, 2021. https://kosis.kr/statisticsList/statisticsListIndex.do?menuId=M_01_01&vwcd=MT_ZTITLE&parmTabId=M_01_01#SelectStatsBoxDiv.

17. Chun JY, Park WB, Kim NJ, Choi EH, Funk S, Oh MD. Estimating contact-adjusted immunity levels against measles in South Korea and prospects for maintaining elimination status. Vaccine. 2020; 38(2):107–111. PMID: 31679860.

18. Chun JY, Jeong H, Beutels P, Ohmagari N, Kim Y, Tsuzuki S. COVID-19 vaccine prioritisation in Japan and South Korea. medRxiv.

19. Wise J. COVID-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines? BMJ. 2021; 373:n1635. PMID: 34167952.

20. Centers for Disease Control and Prevention. Safety of COVID-19 vaccines. Updated 2021. Accessed June 28, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html.

21. Hunter PR. Thrombosis after COVID-19 vaccination. BMJ. 2021; 373:n958. PMID: 33853865.

22. Public Health England. Coronavirus (COVID-19) in the UK. Updated 2021. Accessed July 1, 2021. https://coronavirus.data.gov.uk/.

23. Ryu S, Ali ST, Noh E, Kim D, Lau EH, Cowling BJ. Transmission dynamics and control of two epidemic waves of SARS-CoV-2 in South Korea. BMC Infect Dis. 2021; 21(1):485. PMID: 34039296.